

P.M.: Member of the board – Novartis, Allergan, Bayer; Consultant – Novartis, Allergan, Bayer, Thea, Sanofi.

R.S.: Member of the board – Allergan, Alcon, Alimera, Bayer, Novartis, THEA; Consultant – Novartis; Lecture fees – Bayer, Allergan.

F.B.: Member of the board – Allergan, Novartis, Farmila-Thea, Bayer Schering Pharma, Alcon Inc., Bausch & Lomb, Genentech, Alimera Sciences, Sanofi-Aventis, Thrombogenics Inc., Hoffmann-La Roche Ltd., SIFI SpA, Carl Zeiss SpA, Sooft Italia SpA, Santen Pharmaceutical Ltd., Novagali-Pharma; Consultant – Boehringer-Ingelheim.

M.V.: Member of the board – Allergan, Bayer, Novartis, Sifi.

H.E.: Member of the board – Novartis, Bayer; Lectures fees – Novartis. Educational presentations – Novartis, Bayer, Allergan; Travel accommodations – Novartis, Bayer, Allergan.

S.S.: Grants and personal fees – Bayer, Novartis, Allergan, Roche.

G.M.: Grants – EVICR; Travel accommodations – Novartis.

M.A.: Consultant – Bayer, Novartis, Allergan; Lectures fees – Novartis.

C.C.-G.: Member of the board – Allergan, Bayer, Novartis, Roche, Thea; Grants/grants pending – Thea, Horus, Novartis; Lecture fees – Bayer, Novartis.

D.A.: Grant – Novartis Pharma AG.

S.N.: Employee – AIBILI.

J.C.-V.: Grant – Novartis; Consultant – Aerpio Therapeutics, Alimera Sciences, Allergan, Bayer, Gene Signal, Novartis, Oxular Limited, Pfizer, Retmarker, SA, Roche, Sanofi-Aventis, Vifor Pharma, Zeiss Meditec.

This Investigator Initiated Study was financially supported by Novartis Pharma AG.

HUMAN SUBJECTS: This study includes human subject/tissues. Study protocol was approved by IRB/Ethics Committees (Comitato Etico Centrale IRCCS, Comitato Etico Interaziendale Milano Area A, Comitato Etico per

la Sperimentazione dell’Azienda Ospedaliera di Padova, Comitato Etico Ospedale San Raffaele, West Midlands – Edgbaston Research Ethics Committee, CEIC – Comissão de Ética para a Investigação, CPP Ile-de-France IV). Informed consent was obtained from all human subjects. All tenets of the Declaration of Helsinki were followed.

Author Contributions:

Conception and design: Figueira, Nunes, Cunha-Vaz

Data collection: Figueira, Fletcher, Massin, Silva, Bandello, Midena, Varano, Sivaprasad, Eleftheriadis, Menon, Amaro, Scheer, Creuzot-Garcher, Nascimento, Lobo, Cunha-Vaz

Analysis and interpretation: Figueira, Alves, Cunha-Vaz

Obtained funding: Not applicable

Overall responsibility: Figueira, Fletcher, Massin, Silva, Bandello, Midena, Varano, Sivaprasad, Eleftheriadis, Menon, Amaro, Scheer, Creuzot-Garcher, Nascimento, Alves, Nunes, Lobo, Cunha-Vaz


Abbreviations and Acronyms:

AE = adverse event; **BCVA** = best-corrected visual acuity; **DA** = disc area; **DME** = diabetic macular edema; **ETDRS** = Early Treatment Diabetic Retinopathy Study; **FAS** = full analysis set; **HbA_{1c}** = glycated hemoglobin; **HR-PDR** = high-risk proliferative diabetic retinopathy; **ITV** = intravitreal; **logMAR** = logarithm of the minimum angle of resolution; **NV** = neovascularization; **NVD** = neovascularization at the disc; **NVE** = neovascularization elsewhere; **NVT** = neovascularization total; **PDR** = proliferative diabetic retinopathy; **PP** = per protocol; **PRP** = panretinal photocoagulation; **RBZ** = ranibizumab; **SD** = standard deviation; **VEGF** = vascular endothelial growth factor.

Correspondence:

João Figueira, MD, PhD, AIBILI, Azinhaga de Santa Comba, Celas, 3000-548, Coimbra, Portugal. E-mail: joaofigueira@oftalmologia.co.pt.

Pictures & Perspectives



Direct View of the Angle Structures in Bilateral Congenital Megalocornea

A 3-year-old boy presented to the pediatric ophthalmology department with a diagnosis of bilateral congenital megalocornea. On observation, he had extremely large corneal diameters with minimal sclera show (Fig 1A), and the appearance of large palpebral apertures. There was a corneal optical aberration when viewed from the side (left eye; Fig 1B) and when magnified, it is possible to view the angle structures (right eye; Fig 1C) without the aid of a gonioscopy lens. Apart from the corneas, all anterior segment structures appeared to be normal, with no evidence of glaucoma. He has good vision (logMar 0.00) in each eye.

DAMIEN C.M. YEO, MBChB, FRCOPHTH¹

STEPHANIE FIGG, BSC, MCOPTOM^{1,3}

WILLIAM MOORE, MBChB, FRCOPHTH^{1,2}

¹Clinical and Academic Department of Ophthalmology, Great Ormond Street Hospital for Children, London, United Kingdom;

²Ulferscroft Vision Research Group, University College London Great Ormond Street Institute of Child Health, London, United Kingdom;

³Moorfields Eye Hospital, City Road, London, United Kingdom